

## PROGRAMME

---

### Sunday 3 July

13.00 – 17.30	<b>Registration</b>		
			<b>Main auditorium</b>
15.00	<b>Welcome</b>		Gunilla T. Westermark Uppsala, Sweden
	<b>Chair persons</b> Robert Kisilevsky/Angela Dispenzieri		
15.15 – 16.00	<b>Opening lecture</b> Amyloid and amyloidosis	O-1	Giampaolo Merlini Pavia, Italy
16.00 – 18.00	<b>Basic science</b>		
16.00 – 16.30	<b>Keynote lecture</b> Human protein atlas	O-2	Fredrik Pontén Uppsala, Sweden
16.30 – 16.45	Identifying germline genetic risk factors for immunoglobulin light chain amyloidosis	O-3	Miguel Inacio Da Silva Filho Heidelberg, Germany
16.45 – 17.00	The role of novel biomarkers in AL amyloidosis	O-4	Ga Yeon Lee Seoul, Korea
17.00 – 17.15	Immunotherapy against alpha-synuclein protofibrils as a therapeutic strategy for Parkinson's disease	O-5	Joakim Bergström Uppsala, Sweden
17.15 – 17.30	siRNA targeting the $\kappa$ light chain constant region: A pre-clinical experimental approach to AL and non-fibrillar $\kappa$ light chain deposition diseases	O-6	Xun Ma Boston, MA
17.30 – 17.45	Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic?	O-7	Olga Gursky Boston, MA
17.45 – 18.15	<b>Special lecture</b> A backward glance at what gives us the future	O-8	Robert A. Kyle Rochester, MN
19.00	<b>Welcome reception</b>		Botanical garden

### Monday 4 JULY

			<b>Main auditorium</b>
	<b>Chair persons</b> Marcus Fändrich/Jeffrey W. Kelly		
08.00	<b>Basic science</b>		
08.00 – 08.30	<b>Keynote lecture</b> Chaperone in amyloidosis	O-9	Jan Johansson Stockholm, Sweden
08.30 – 09.00	<b>Keynote lecture</b> Amyloid and amyloids	O-10	David Eisenberg Los Angeles, CA

09.00 – 09.15	A bifunctional peptide, “peptope”, for pre-targeting antibody 7D8 to systemic amyloid deposits.	O-11	Jonathan Wall Knoxville, TN
09.15 – 09.30	Acceleration of $\alpha$ -synuclein aggregation	O-12	Ricardo Gaspar Lund, Sweden
09.30 – 09.45	Carbamylation of the amino-terminal residue (Gly 1) of mouse SAA1.1 promotes amyloid fibril formation	O-13	Barbara Kluge-Beckerman Indianapolis, IN
09.45 – 10.15	<b>Coffee break</b>		
	<b>Chair persons</b> Jan Johansson/Joel N. Buxbaum		
10.15 – 12.00	<b>Basic science</b>		
10.15 – 10.45	<b>Keynote lecture</b> Seeding and cross-seeding	O-14	Christopher M. Dobson Cambridge, UK
10.45 – 11.00	Co-fibrillogenesis of wild-type and D76N $\beta$ 2-microglobulin seeding effect or prion-like mechanism?	O-15	Vittorio Bellotti Pavia, Italy and London, UK
11.00 – 11.15	Molecular determinants of IAPP cross-amyloid interaction with Abeta	O-16	Aphrodite Kapurniotu Munich, Germany
11.15 – 11.30	Cross-seeding of medin and A-beta amyloid	O-17	Hannah Davies Liverpool, UK
11.30 – 12.00	<b>Keynote lecture</b> Treatment in pipeline	O-18	Sir Mark B. Pepys London, UK
12.00 – 13.30	<b>Lunch and poster viewing</b>		
	<b>Chair persons</b> Maria Picken/Vaishali Sanchorawala		
13.30 – 15.00	<b>Imaging</b>		
13.30 – 14.00	<b>Keynote lecture</b> <i>In vivo</i> detection of amyloid	O-19	Philip N. Hawkins London, UK
14.00 – 14.15	Regression of cardiac AL amyloidosis demonstrated by cardiovascular magnetic resonance: a new era of understanding	O-20	Ana Martinez Naharro London, UK
14.15 – 14.30	Visualisation of transthyretin heart amyloidosis by $^{11}\text{C}$ -PIB and PET	O-21	Björn Pilebro Umeå, Sweden
14.30 – 14.45	Multicenter experience of planar technetium pyrophosphate cardiac imaging: Does preferential cardiac uptake predict survival in patients with ATTR cardiac amyloidosis?	O-22	Adam Castano New York, NY
14.45 – 15.00	Cardiac amyloid imaging with $^{18}\text{F}$ -florbetaben positron emission tomography: a pilot study	O-23	Peter Mollee Queensland, Australia
15.00 – 15.30	<b>Coffee break</b>		
	<b>Chair persons</b> Gunilla Westermark/Ole Suhr		
15.30 – 17.00	<b>Transthyretin</b>		
15.30 – 16.00	<b>Keynote lecture</b> Transthyretin	O-24	Merrill D. Benson Indianapolis, IN
16.00 – 16.30	<b>Keynote lecture</b> Antibodies in TTR-amyloidosis	O-25	Yukio Ando Kumamoto, Japan
16.30 – 18.00	<b>Poster presentations</b>		
19.00 – 21.00	<b>Satellite symposium</b> Alnylam		<b>Main auditorium</b>

# Tuesday 5 July

			Main auditorium
08.00 – 10.00	<b>Non-hereditary and hereditary ATTR amyloidosis</b>		
08.00 – 09.30	Pathways for ATTR amyloid formation Presentations and discussion	O-26 O-27 O-28 O-29 O-30	Vittorio Bellotti, Pavia, Italy and London, UK David Eisenberg, Los Angeles, CA Jeffrey W. Kelly, La Jolla, CA (Chair) Ole B. Suhr, Umeå, Sweden Per Westermark, Uppsala, Sweden
	<b>Chair persons</b> Yukio Ando/Marcia W. Cruz		
9.30 – 09.45	Retinol Binding Protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis	O-31	Frederick Ruberg Boston, MA
09.45 – 10.00	Establishment of a diagnostic center for amyloidosis in Japan by Kumamoto University	O-32	Taro Yamashita Kumamoto, Japan
10.00 – 10.30	<b>Coffee break</b>		
10.30 – 10.45	Male gender is a risk factor for myocardial involvement in transthyretin-related amyloidosis: A study based on the Transthyretin Amyloid Outcomes Survey	O-33	Claudio Rapezzi Bologna, Italy
10.45 – 11.00	Unveiling transthyretin cardiac amyloidosis as an etiology for paradoxical low-flow severe aortic stenosis in patients undergoing transcatheter aortic valve replacement	O-34	Adam Castano New York, NY
11.00 – 13.00	<b>Satellite symposium</b> <b>Pfizer</b>		<b>Main auditorium</b>
13.00 – 14.00	<b>Lunch</b>		
14.00 –	<b>AL amyloidosis</b>		
	<b>Chair persons</b> Arnoud Jaccard/Ute Hegenbart		
14.00 – 14.30	<b>Keynote lecture</b> AL amyloidosis	O-35	Raymond L. Comenzo Boston, MA
14.30 – 14.45	Limited duration treatment with bortezomib and methylprednisone is effective in primary amyloidosis leading to results similar to those of high dose melphalan	O-36	Rafat Abonour Indianapolis, IN
14.45 – 15.00	Renal outcome among patients with systemic AL amyloidosis who present with advanced CKD is dependent on speed and magnitude of response to chemotherapy	O-37	Tamer Rezk London, UK
15.00 – 15.15	CS-1 chimeric antigen receptor adoptive T cell therapy for systemic light chain amyloidosis	O-38	Xiuli Wang Vuarde, CA
15.15 – 15.30	NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study	O-39	Morie A. Gertz Rochester, MN
15.30 – 17.00	<b>Coffee and poster presentations</b>		
17.00 – 18.00	<b>Refreshments/dinner</b>		
18.00 – 19.30	<b>Satellite symposium</b> <b>Prothena</b>		<b>Main auditorium</b>

# Wednesday 6 July

			Main auditorium
	<b>More AL amyloidosis</b>		
08.00 - 09.15	<b>Debate</b> Treatment of AL amyloidosis Stem cell transplantation or chemotherapy for front-line treatment of AL?	O-40 O-41 O-42 O-43	Morie A. Gertz, Rochester, MN Stephan Schönland, Heidelberg, Germany (Chair) Stephan Schönland, Heidelberg, Germany Martha Skinner, Boston, MA
09.15 - 09.30	A randomized phase iii trial of melphalan and dexamethasone (mdex) versus bortezomib, melphalan and dexamethasone (bmdex) for untreated patients with AL amyloidosis	See PB-86	Giovanni Palladini Pavia, Italy
09.30 - 10.00	<b>Coffee break</b>		
10.00 - 11.00	<b>AA amyloidosis</b>		
	<b>Chair persons</b> Steven Zeldenrust/Lawreen Connors		
10.00 - 10.30	<b>Keynote lecture</b> Pathogenesis and status of AA amyloidosis	O-44	Bouke P.C. Hazenberg Groningen, the Netherlands
10.30 - 10.45	AA amyloidosis related to familial mediterranean fever: a cohort study of 31 cases	O-45	Sophie Georjin-Lavialle Paris, France
10.45 - 11.00	Transcriptional upregulation and sequence variation in the SAA gene pathway in island foxes ( <i>Urocyon littoralis</i> ) with AA amyloidosis	O-47	Patricia Gaffney La Jolla, CA
11.00 - 12.30	<b>Satellite symposium</b> <b>Bellus</b>		<b>Main auditorium</b>
12.30 - 14.00	<b>Lunch and Poster presentations</b>		
	<b>Chair persons</b> Arie Stangou/Keiichi Higuchi		
14.00 - 15.05	<b>More AA</b> <b>Other amyloid forms</b>		
14.00 - 14.15	A clinical Phase 3 confirmatory trial of Kiacta™ in the treatment of AA amyloidosis	O-48	Giampaolo Merlini Pavia, Italy
14.15 - 14.30	Passive treatment with monoclonal antibodies to islet amyloid polypeptide significantly improved both haemoglobin A1c and glucose tolerance and decreased extracellular amyloid deposits in the transgenic HIP rat model of type 2 diabetes	O-49	Wagner Zago San Francisco, CA
14.30 - 14.45	Prevalence of monoclonal gammopathy of unknown significance in ATTR-wild type patients	O-50	Hallie Geller Boston, MA
14.45 - 15.05	Apolipoprotein C-II amyloidosis	O-51 O-52	Laura Obici, Pavia, Italy Samih Nasr, Rochester, MN
15.05 - 15.30	<b>Coffee break</b>		
15.30 - 17.30	<b>Parallel sessions:</b> A. Liver and heart transplantation in amyloidosis B. Animal models		<b>A. In Main auditorium</b> <b>B. In Hall B</b>
15.30 - 17.30	<b>A. Liver and heart transplantation in amyloidosis</b>		<b>Main auditorium</b>
	<b>Chair persons</b> Bo-Göran Ericzon/Philip Hawkins		

15.30 – 16.00	<b>Keynote lecture</b> Liver transplantation	O-53	Bo-Göran Ericzon Stockholm, Sweden
16.00 – 16.30	<b>Keynote lecture</b> Heart transplantation	O-54	Mathew Maurer New York, NY
16.30 – 16.45	Transthyretin-type cerebral amyloid angiopathy in post-transplant patients with hereditary ATTR amyloidosis: Correlates between clinical findings and PIB-PET imaging	O-55	Yoshiki Sekijima Matsumoto, Japan
16.45 – 17.00	Evaluation of central nervous complications following liver transplantation in patients with hereditary transthyretin amyloidosis	O-56	Nicklas Wange Umeå, Sweden
17.00 – 17.15	Polyneuropathy after FAP domino liver transplantation	O-57	Göran Solders, Stockholm, Sweden
17.15 – 17.30	Cardiac dysautonomia predicts long term survival in hereditary transthyretin amyloidosis after liver transplantation	O-58	Michel Slama Paris, France
15.30 – 17.30	<b>B. Animal models</b>		<b>Hall B</b>
15.30 – 16.45	Presentations and discussion: Experimental animal models	O-59 O-60 O-61 O-62	Joel N. Buxbaum, La Jolla CA (Chair) Francesca Lavatelli, Pavia, Italy Maria J. Saraiva, Porto, Portugal Gunilla T. Westermark, Uppsala, Sweden
	<b>Chair persons</b> Jean D. Sipe/Joel Buxbaum		
16.45 – 17.00	Exploring the mechanism of cardiotoxicity in AL amyloidosis: the C. elegans model	O-63	Paola Rognoni Pavia, Italy
17.00 – 17.15	Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomenigeal animal model	O-64	Maria J. Saraiva Porto, Portugal
17.15 – 17.30	Serum amyloid A in the treatment of sepsis in a mouse model	O-65	Reinhold P. Linke Martinsreid, Germany
19.00	<b>Dinner at Uppsala Castle</b>		

## Thursday 7 July

08.00 – 10.00	<b>Parallel sessions</b>		
	<b>General discussions</b>		
08.00 – 09.15	<b>Discussion I</b> Suitable methodology for treatment evaluation	O-66 O-67 O-68	<b>Main auditorium</b> Teresa Coelho; Porto, Portugal Thibaud Damy, Paris, France Steven Zeldenrust, Rochester, MN (Chair)
	<b>Chair persons</b> Teresa Coelho/Raymond Comenzo		

09.15 – 09.30	The 6-minute walk test in AL amyloidosis patients: a single center experience	O-69	Vina Pulido Boston, MA
09.30 – 09.45	Lessons for future clinical trial design in cardiac amyloidosis - the experience of a prospective study in stage III cardiac AL amyloidosis (REVEAL study)	O-70	Ashutosh Wechalekar, London, UK
09.45 – 10.00	Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in a Stem Cell-Based in vitro Model	O-71	Christoph Niemietz Munster, Germany
10.00 – 10.15	Treatment of transthyretin cardiomyopathy with a TTR specific antisense oligonucleotide (IONIS-TTR Rx)	O-72	Merrill D. Benson Indianapolis, IN
08.00 – 09.15	<b>Discussion II</b> ThT assay pitfalls- can the method be standardised?	O-73 O-74 O-75 O-76	<b>Hall B</b> Jeffrey W. Kelly, La Jolla, CA Hironobu Naiki, Fukui, Japan Sofie Nyström, Linköping, Sweden Daniel Otzen, Aarhus, Denmark (Chair)
	<b>Chair persons</b> Daniel Otzen/Per Westermark		
09.15 – 09.30	FRET-based observation of intracellular SAA fibril formation	O-77	Stephanie Claus Ulm, Germany
09.30 – 09.45	First report of MYD88 L265P somatic mutation in IgM-associated light chain amyloidosis	O-78	Rajshekhkar Chakraborty Rochester, MN
09.45 – 10.00	Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding	O-79	Marta Marin-Argany Knoxville, TN
10.00 – 10.15	Discovery of transthyretin stabilizers displaying resilience to the effect of the V30M mutation	O-80	Rui Brito Porto, Portugal
10.15 – 10.45	<b>Coffee</b>		
10.45 – 11.30	ISA members meeting: Report on the journal Amyloid (Per Westermark, editor). Election results. Future symposia.		Bouke P.C. Hazenberg/Angela Dispenzieri
11.30 – 12.00	<b>Summary of the meeting</b>		<b>Main auditorium</b> Martha Skinner Boston, MA
12.00	<b>Closing remarks</b>		Gunilla T. Westermark Ole B. Suhr Per Westermark
12.30 – 13.30	<b>Grab &amp; go lunch</b>		